查看購物車
  • Simplified Chinese
  • English
封面
市場調查報告書
商品編碼
1678794

全球無標記檢測市場 - 2025 年至 2033 年

Global Label-Free Detection Market - 2025-2033
出版日期: | 出版商: DataM Intelligence | 英文 220 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

2024 年全球無標記檢測市場規模達到 6.4483 億美元，預計到 2033 年將達到 12.5149 億美元，2025-2033 年預測期內的複合年成長率為 7.5%。

無標記檢測是一種先進的分析技術，無需螢光、放射性或酵素標記即可測量分子物理性質的變化。它提供有關結合動力學、親和力和濃度的即時資料，使其廣泛應用於藥物發現、先導最佳化和生物製藥研究。它簡化了工作流程，縮短了檢測開發時間，並允許以最少的樣品製備來分析複雜的生物樣品。

市場動態：

促進因素與約束因素

對先進藥物發現和開發流程的需求不斷成長

無標記檢測市場受到對先進藥物發現和開發流程日益成長的需求的推動。製藥和生物技術公司更喜歡這些技術來即時、準確地測量生物分子相互作用，提高資料品質並減少標籤干擾。對生物製藥、生物相似藥和個人化醫療的關注加速了這些技術的採用，使得對複雜生物分子和標靶治療的詳細分析成為可能。

此外，無標記檢測技術透過提供減少偽影的生物相關資料，徹底改變了藥物研發。這些方法消除了對染料、標籤或基因改造細胞的需求，從而可以使用天然細胞並更準確地表示生物相互作用。它們還提供增強的靈敏度、即時動力學和多目標分析。應用包括表現型篩選、目標識別和驗證、命中到先導化合物最佳化和毒性評估。

靈敏度和檢測範圍有限

無標記檢測技術由於其靈敏度和檢測範圍有限，在市場上面臨挑戰。這些系統提供即時分析，但在檢測低豐度生物分子或弱分子相互作用時可能會受到影響，尤其是在複雜的生物樣本中。這會影響早期生物標記發現、診斷和藥物篩選等關鍵應用的準確性和可靠性。傳統的標記檢測方法可能仍然是首選，這可能會限制無標記技術在超靈敏檢測應用中的採用。

目錄

第 1 章：方法與範圍

第 2 章：定義與概述

第 3 章：執行摘要

第 4 章：動態

  • 影響因素
    • 驅動程式
      • 對先進藥物發現和開發流程的需求不斷成長
    • 限制
      • 靈敏度和檢測範圍有限
    • 機會
    • 影響分析

第5章：戰略洞察與產業展望

  • 市場領導者和先驅者
    • 新興先鋒和傑出參與者
    • 擁有最大銷售品牌的成熟領導者
    • 擁有成熟產品的市場領導者
  • CXO 觀點
  • 最新進展與突破
  • 案例研究/正在進行的研究
  • 監管和報銷情況
    • 北美洲
    • 歐洲
    • 亞太地區
    • 拉丁美洲
    • 中東和非洲
  • 波特五力分析
  • 供應鏈分析
  • 專利分析
  • SWOT 分析
  • 未滿足的需求和差距
  • 市場進入和擴張的推薦策略
  • 情境分析：最佳情況、基本情況和最壞情況預測
  • 定價分析和價格動態
  • 關鍵意見領袖

第 6 章：依產品類型

  • 儀器
  • 耗材
  • 軟體和服務

第 7 章：按技術

  • 表面等離子體共振 (SPR)
  • 生物層干涉測量法（BLI）
  • 等溫滴定量熱法 (ITC)
  • 差示掃描量熱法（DSC）
  • 其他

第 8 章：按應用

  • 藥物研發
  • 結合動力學和熱力學
  • 確認點擊和潛在客戶生成
  • 內源性受體檢測
  • 其他

第 9 章：按最終用戶

  • 製藥和生物技術公司
  • 學術及研究機構
  • 合約研究組織 (CRO)
  • 其他

第 10 章：按地區

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 西班牙
    • 義大利
    • 歐洲其他地區
  • 南美洲
    • 巴西
    • 阿根廷
    • 南美洲其他地區
  • 亞太
    • 中國
    • 印度
    • 日本
    • 韓國
    • 亞太其他地區
  • 中東和非洲

第 11 章：競爭格局

  • 競爭格局
  • 市場定位/佔有率分析
  • 併購分析

第 12 章：公司簡介

  • Danaher Corporation
    • 公司概況
    • 產品組合
      • 產品描述
      • 產品關鍵績效指標 (KPI)
      • 歷史和預測產品銷售量
      • 產品銷售量
    • 財務概覽
      • 公司收入
      • 地區收入佔有率
      • 收入預測
    • 主要進展
      • 合併與收購
      • 關鍵產品開發活動
      • 監管部門批准等
    • SWOT 分析
  • PerkinElmer, Inc
  • Agilent Technologies, Inc
  • Sartorius AG
  • Thermo Fisher Scientific Inc
  • Corning Incorporated
  • Bruker Corporation
  • HORIBA, Ltd.
  • Reichert, Inc
  • Malvern Panalytical Ltd
  • Similar data will be provided for each market player.
  • 阿塔納空軍基地
    • 管道產品描述
    • 產品關鍵績效指標 (KPI)
    • 主要活動
    • 市場進入時間表
    • 產品滲透率
    • 銷售估計和預測
  • 尼可亞
  • 不受束縛的實驗室
  • 奈米溫度技術有限公司
  • 克瑞普蒂克斯公司
  • 將為每個市場參與者提供類似的資料。

第 13 章：附錄

簡介目錄
Product Code: BT9289

The Global Label-Free detection market reached US$ 644.83 million in 2024 and is expected to reach US$ 1,251.49 million by 2033, growing at a CAGR of 7.5% during the forecast period 2025-2033.

Label-free detection is an advanced analytical technique that measures changes in the physical properties of molecules without the need for fluorescent, radioactive, or enzymatic labels. It provides real-time data on binding kinetics, affinity, and concentration, making it widely used in drug discovery, lead optimization, and biopharmaceutical research. It streamlines workflows, reduces assay development time, and allows for the analysis of complex biological samples with minimal sample preparation.

Market Dynamics: Drivers & Restraints

Growing Demand for Advanced Drug Discovery and Development Processes

The label-free detection market is driven by the increasing demand for advanced drug discovery and development processes. Pharmaceutical and biotechnology companies prefer these technologies for real-time, accurate measurement of biomolecular interactions, improving data quality and reducing label interference. The focus on biopharmaceuticals, biosimilars, and personalized medicine has accelerated the adoption of these technologies, enabling detailed analysis of complex biological molecules and targeted therapies.

Moreover, Label-free detection technologies are revolutionizing drug discovery by providing biologically relevant data with reduced artifacts. These methods eliminate the need for dyes, tags, or genetically modified cells, allowing for native cells and a more accurate representation of biological interactions. They also offer enhanced sensitivity, real-time kinetics, and multi-target profiling. Applications include phenotypic screening, target identification and validation, hit-to-lead optimization, and toxicity assessment.

Limited Sensitivity and Detection Range

Label-free detection technologies face challenges in the market due to their limited sensitivity and detection range. These systems offer real-time analysis but can be compromised when detecting low-abundance biomolecules or weak molecular interactions, especially in complex biological samples. This affects accuracy and reliability in critical applications like early-stage biomarker discovery, diagnostics, and drug screening. Traditional labeled detection methods may still be preferred, potentially limiting the adoption of label-free technologies in ultra-sensitive detection applications.

Segment Analysis

The global label-free detection market is segmented based on product type, technology, application, end user, and region.

The instruments in the product type segment are expected to dominate with the highest market share.

Instruments are crucial in the label-free detection, enabling the real-time study of biomolecular interactions. Advanced instruments like SPR analyzers, BLI systems, and ITC devices accurately measure binding kinetics, affinity, and thermodynamics without fluorescent or radioactive labels. Due to their rapid, reliable, and label-free results, these instruments are increasingly used in drug discovery, lead optimization, and biopharmaceutical development. Innovation in design, automation, and sensitivity enhancement is increasing demand across pharmaceutical, biotechnology, and research sectors.

For instance, in October 2024, Max Planck Institute researchers developed a method for precisely detecting small liquid quantities, down to micromolar levels, with exceptional sensitivity in the near-infrared spectrum. This breakthrough opens doors to advanced, label-free bio-imaging techniques for detecting target molecules in aqueous environments, pushing biomedical applications' boundaries.

Pharmaceutical and biotechnology companies in the end-user segment are the dominating with the highest market share.

The global label-free detection market is primarily driven by pharmaceutical and biotechnology companies, who rely on these technologies for drug discovery, biotherapeutics development, and biologics research. These companies use label-free systems for high-throughput screening, complex biological interactions analysis, and real-time data generation without labeling interferences. As the pharmaceutical industry shifts towards precision medicine, biologics, and small molecule therapeutics, demand for label-free detection technologies is expected to surge, solidifying their position as a primary growth driver.

Geographical Analysis

North America is expected to hold a significant position in the label-free detection market share

North America holds a substantial position in the label-free detection market due to the presence of a robust pharmaceutical and biotechnology sector, significant research investments, and prominent players like Danaher Corporation, Thermo Fisher Scientific, and Agilent Technologies. Also, the region's focus on drug discovery, early technology adoption, and government support for life sciences research fuel market growth. Market players' innovation in the region is a key driver for market growth in North America.

For instance, in February 2024, Agilent Technologies integrated the xCELLigence RTCA HT platform with the BioTek BioSpa 8 Automated Incubator, providing a non-invasive, label-free, kinetic readout of cell proliferation and cytotoxicity, thereby increasing throughput and decreasing sample sizes.

Competitive Landscape

The major global players in the label-free detection market include Danaher Corporation, PerkinElmer, Inc, Agilent Technologies, Inc, Sartorius AG, Thermo Fisher Scientific Inc, Corning Incorporated, Bruker Corporation, HORIBA, Ltd, Reichert, Inc, and Malvern Panalytical Ltd, among others.

Why Purchase the Report?

  • Pipeline & Innovations: Reviews ongoing clinical trials, product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
  • Product Performance & Market Positioning: Analyze product performance, market positioning, and growth potential to optimize strategies.
  • Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
  • Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
  • Market Updates & Industry Changes: This covers recent regulatory changes, new policies, and emerging technologies.
  • Competitive Strategies: Analyze competitor strategies, market share, and emerging players.
  • Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
  • Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
  • Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
  • Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
  • Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
  • Post-market Surveillance: Uses post-market data to enhance product safety and access.
  • Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The global Label-Free Detection market report delivers a detailed analysis with 61 key tables, more than 59 visually impactful figures, and 220 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2024

  • Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
  • Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
  • Product Type & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
  • Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
  • Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
  • Supply Chain: Distribution and Supply Chain Managers.
  • Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
  • Academic & Research: Academic Institutions.

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Product Type
  • 3.2. Snippet by Technology
  • 3.3. Snippet by Application
  • 3.4. Snippet by End User
  • 3.5. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Growing Demand for Advanced Drug Discovery and Development Processes
    • 4.1.2. Restraints
      • 4.1.2.1. Limited Sensitivity and Detection Range
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Strategic Insights and Industry Outlook

  • 5.1. Market Leaders and Pioneers
    • 5.1.1. Emerging Pioneers and Prominent Players
    • 5.1.2. Established leaders with largest selling Brand
    • 5.1.3. Market leaders with established Product
  • 5.2. CXO Perspectives
  • 5.3. Latest Developments and Breakthroughs
  • 5.4. Case Studies/Ongoing Research
  • 5.5. Regulatory and Reimbursement Landscape
    • 5.5.1. North America
    • 5.5.2. Europe
    • 5.5.3. Asia Pacific
    • 5.5.4. Latin America
    • 5.5.5. Middle East & Africa
  • 5.6. Porter's Five Forces Analysis
  • 5.7. Supply Chain Analysis
  • 5.8. Patent Analysis
  • 5.9. SWOT Analysis
  • 5.10. Unmet Needs and Gaps
  • 5.11. Recommended Strategies for Market Entry and Expansion
  • 5.12. Scenario Analysis: Best-Case, Base-Case, and Worst-Case Forecasts
  • 5.13. Pricing Analysis and Price Dynamics
  • 5.14. Key Opinion Leaders

6. By Product Type

  • 6.1. Introduction
    • 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 6.1.2. Market Attractiveness Index, By Product Type
  • 6.2. Instruments*
    • 6.2.1. Introduction
    • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 6.3. Consumables
  • 6.4. Software and Services

7. By Technology

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 7.1.2. Market Attractiveness Index, By Technology
  • 7.2. Surface Plasmon Resonance (SPR)*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Bio-layer interferometry (BLI)
  • 7.4. Isothermal Titration Calorimetry (ITC)
  • 7.5. Differential Scanning Calorimetry (DSC)
  • 7.6. Others

8. By Application

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.1.2. Market Attractiveness Index, By Application
  • 8.2. Drug Discovery and Development*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Binding Kinetics and Thermodynamics
  • 8.4. Hit Confirmation and Lead Generation
  • 8.5. Endogenous Receptor Detection
  • 8.6. Others

9. By End User

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 9.1.2. Market Attractiveness Index, By End User
  • 9.2. Pharmaceutical and Biotechnology Companies*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 9.3. Academic and Research Institutes
  • 9.4. Contract Research Organizations (CROs)
  • 9.5. Other

10. By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 10.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.2.7.1. U.S.
      • 10.2.7.2. Canada
      • 10.2.7.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 10.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.3.7.1. Germany
      • 10.3.7.2. U.K.
      • 10.3.7.3. France
      • 10.3.7.4. Spain
      • 10.3.7.5. Italy
      • 10.3.7.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 10.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.4.7.1. Brazil
      • 10.4.7.2. Argentina
      • 10.4.7.3. Rest of South America
  • 10.5. Asia-Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 10.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.5.7.1. China
      • 10.5.7.2. India
      • 10.5.7.3. Japan
      • 10.5.7.4. South Korea
      • 10.5.7.5. Rest of Asia-Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User

11. Competitive Landscape

  • 11.1. Competitive Scenario
  • 11.2. Market Positioning/Share Analysis
  • 11.3. Mergers and Acquisitions Analysis

12. Company Profiles

Key Market Players

  • 12.1. Danaher Corporation*
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio
      • 12.1.2.1. Product Description
      • 12.1.2.2. Product Key Performance Indicators (KPIs)
      • 12.1.2.3. Historic and Forecasted Product Sales
      • 12.1.2.4. Product Sales Volume
    • 12.1.3. Financial Overview
      • 12.1.3.1. Company Revenue's
      • 12.1.3.2. Geographical Revenue Shares
      • 12.1.3.3. Revenue Forecasts
    • 12.1.4. Key Developments
      • 12.1.4.1. Mergers & Acquisitions
      • 12.1.4.2. Key Product Development Activities
      • 12.1.4.3. Regulatory Approvals, etc.
    • 12.1.5. SWOT Analysis
  • 12.2. PerkinElmer, Inc
  • 12.3. Agilent Technologies, Inc
  • 12.4. Sartorius AG
  • 12.5. Thermo Fisher Scientific Inc
  • 12.6. Corning Incorporated
  • 12.7. Bruker Corporation
  • 12.8. HORIBA, Ltd.
  • 12.9. Reichert, Inc
  • 12.10. Malvern Panalytical Ltd
  • Similar data will be provided for each market player.

Emerging Market Players

  • 12.11. Attana AB*
    • 12.11.1. Pipeline Products Description
    • 12.11.2. Product Key Performance Indicators (KPIs)
    • 12.11.3. Key Activities
    • 12.11.4. Market Entry Timelines
    • 12.11.5. Product Penetration Rate
    • 12.11.6. Sales Estimation and Projections
  • 12.12. Nicoya
  • 12.13. Unchained Labs
  • 12.14. Nanotemper Technologies GmbH
  • 12.15. Creoptix AG
  • Similar data will be provided for each market player.

LIST NOT EXHAUSTIVE

13. Appendix

  • 13.1. About Us and Services
  • 13.2. Contact Us